BR112014031616B1 - Fenoxietil piperidina, seu sal de cloridrato, e composição farmacêutica - Google Patents

Fenoxietil piperidina, seu sal de cloridrato, e composição farmacêutica Download PDF

Info

Publication number
BR112014031616B1
BR112014031616B1 BR112014031616-3A BR112014031616A BR112014031616B1 BR 112014031616 B1 BR112014031616 B1 BR 112014031616B1 BR 112014031616 A BR112014031616 A BR 112014031616A BR 112014031616 B1 BR112014031616 B1 BR 112014031616B1
Authority
BR
Brazil
Prior art keywords
mmol
methyl
compound
formula
mixture
Prior art date
Application number
BR112014031616-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014031616A2 (pt
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of BR112014031616A2 publication Critical patent/BR112014031616A2/pt
Publication of BR112014031616B1 publication Critical patent/BR112014031616B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014031616-3A 2012-06-29 2013-06-20 Fenoxietil piperidina, seu sal de cloridrato, e composição farmacêutica BR112014031616B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US61/665,951 2012-06-29
US201361779099P 2013-03-13 2013-03-13
US61/779,099 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (2)

Publication Number Publication Date
BR112014031616A2 BR112014031616A2 (pt) 2017-06-27
BR112014031616B1 true BR112014031616B1 (pt) 2022-06-21

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014031616-3A BR112014031616B1 (pt) 2012-06-29 2013-06-20 Fenoxietil piperidina, seu sal de cloridrato, e composição farmacêutica

Country Status (42)

Country Link
US (2) US8962659B2 (enExample)
EP (1) EP2867207B1 (enExample)
JP (1) JP6127136B2 (enExample)
KR (1) KR101653476B1 (enExample)
CN (1) CN104411684B (enExample)
AP (1) AP2014008164A0 (enExample)
AR (1) AR091429A1 (enExample)
AU (1) AU2013280875B2 (enExample)
BR (1) BR112014031616B1 (enExample)
CA (1) CA2875569C (enExample)
CL (1) CL2014003535A1 (enExample)
CO (1) CO7151507A2 (enExample)
CR (1) CR20140553A (enExample)
CY (1) CY1119425T1 (enExample)
DK (1) DK2867207T3 (enExample)
DO (1) DOP2014000287A (enExample)
EA (1) EA024392B1 (enExample)
EC (1) ECSP14033267A (enExample)
ES (1) ES2644812T3 (enExample)
GT (1) GT201400288A (enExample)
HR (1) HRP20171515T1 (enExample)
HU (1) HUE034425T2 (enExample)
IL (1) IL236219A (enExample)
JO (1) JO3296B1 (enExample)
LT (1) LT2867207T (enExample)
MA (1) MA37686B1 (enExample)
ME (1) ME02840B (enExample)
MX (1) MX345324B (enExample)
MY (1) MY173878A (enExample)
NZ (1) NZ701933A (enExample)
PE (1) PE20150182A1 (enExample)
PH (1) PH12015500009B1 (enExample)
PL (1) PL2867207T3 (enExample)
PT (1) PT2867207T (enExample)
RS (1) RS56452B1 (enExample)
SG (1) SG11201408641UA (enExample)
SI (1) SI2867207T1 (enExample)
TN (1) TN2014000501A1 (enExample)
TW (1) TWI599561B (enExample)
UA (1) UA114325C2 (enExample)
WO (1) WO2014004229A1 (enExample)
ZA (1) ZA201408632B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
DK3083562T3 (da) * 2013-12-17 2017-11-13 Lilly Co Eli Cykliske phenoxyethylaminderivater og deres aktivitet som EP4-receptormodulatorer
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN110621671A (zh) 2017-05-18 2019-12-27 爱杜西亚药品有限公司 作为pge2受体调节剂的苯并呋喃及苯并噻吩衍生物
LT3625224T (lt) 2017-05-18 2021-10-25 Idorsia Pharmaceuticals Ltd N-pakeistieji indolo dariniai
TW201900180A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 嘧啶衍生物
LT3625222T (lt) 2017-05-18 2021-11-10 Idorsia Pharmaceuticals Ltd Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai
PT3625228T (pt) 2017-05-18 2021-09-16 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores dos recetores de pge2
CN111989311B (zh) * 2019-01-22 2022-03-22 凯复(苏州)生物医药有限公司 抑制pge2/ep4信号传导的化合物、其制备方法及其在医药上的应用
JPWO2022102731A1 (enExample) 2020-11-13 2022-05-19
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
DE60307607T2 (de) * 2002-03-18 2007-08-09 Pfizer Products Inc., Groton Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
EP1585729A1 (en) * 2003-01-10 2005-10-19 F.Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
AP2006003534A0 (en) * 2003-09-03 2006-04-30 Pfizer Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
US20050105732A1 (en) * 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
BRPI0510666A (pt) * 2004-05-04 2007-12-04 Pfizer compostos de amida de arila ou heteroarila de metila substituìda, composições farmacêuticas compreendendo os mesmos, uso e combinação
JP4054369B2 (ja) * 2004-05-04 2008-02-27 ファイザー株式会社 オルト置換アリールまたはヘテロアリールアミド化合物
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
JP5244091B2 (ja) 2006-04-24 2013-07-24 メルク カナダ インコーポレイテッド Ep4受容体アンタゴニストとしてのインドールアミド誘導体
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
MX341482B (es) 2010-02-22 2016-08-22 Raqualia Pharma Inc Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
PT2619182T (pt) * 2010-09-21 2017-01-17 Eisai R&D Man Co Ltd Composição farmacêutica
EP2729141B1 (en) * 2011-07-04 2015-12-09 Rottapharm Biotech S.r.l. Cyclic amine derivatives as ep4 receptor agonists
US9181279B2 (en) 2011-07-04 2015-11-10 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor antagonists
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين

Also Published As

Publication number Publication date
PT2867207T (pt) 2017-11-01
JO3296B1 (ar) 2018-09-16
TW201412717A (zh) 2014-04-01
AP2014008164A0 (en) 2014-12-31
CN104411684B (zh) 2016-08-24
TN2014000501A1 (en) 2016-03-30
EP2867207A1 (en) 2015-05-06
EP2867207B1 (en) 2017-08-09
PH12015500009A1 (en) 2015-03-02
TWI599561B (zh) 2017-09-21
EA201492255A1 (ru) 2015-03-31
AR091429A1 (es) 2015-02-04
PH12015500009B1 (en) 2020-10-09
RS56452B1 (sr) 2018-01-31
CO7151507A2 (es) 2014-12-29
HK1203937A1 (en) 2015-11-06
CY1119425T1 (el) 2018-03-07
PE20150182A1 (es) 2015-02-13
EA024392B1 (ru) 2016-09-30
CA2875569C (en) 2016-04-19
DK2867207T3 (en) 2017-09-11
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
KR20150013893A (ko) 2015-02-05
SI2867207T1 (sl) 2017-10-30
NZ701933A (en) 2017-01-27
HUE034425T2 (en) 2018-02-28
SG11201408641UA (en) 2015-01-29
US8962659B2 (en) 2015-02-24
AU2013280875B2 (en) 2015-09-24
PL2867207T3 (pl) 2018-01-31
LT2867207T (lt) 2017-10-10
JP6127136B2 (ja) 2017-05-10
MX345324B (es) 2017-01-25
MX2014015953A (es) 2015-07-17
US9402838B2 (en) 2016-08-02
BR112014031616A2 (pt) 2017-06-27
IL236219A0 (en) 2015-02-01
AU2013280875A1 (en) 2014-12-04
JP2015522018A (ja) 2015-08-03
UA114325C2 (uk) 2017-05-25
KR101653476B1 (ko) 2016-09-01
WO2014004229A1 (en) 2014-01-03
US20150126555A1 (en) 2015-05-07
IL236219A (en) 2017-12-31
ZA201408632B (en) 2017-06-28
MA37686B1 (fr) 2017-04-28
ES2644812T3 (es) 2017-11-30
CA2875569A1 (en) 2014-01-03
DOP2014000287A (es) 2015-01-31
GT201400288A (es) 2015-08-27
CL2014003535A1 (es) 2015-05-08
CR20140553A (es) 2015-02-04
MY173878A (en) 2020-02-26
HRP20171515T1 (hr) 2017-11-17
ME02840B (me) 2018-01-20
US20140005226A1 (en) 2014-01-02
MA37686A1 (fr) 2016-09-30

Similar Documents

Publication Publication Date Title
BR112014031616B1 (pt) Fenoxietil piperidina, seu sal de cloridrato, e composição farmacêutica
JP6212644B2 (ja) フェノキシエチル環状アミン誘導体およびep4受容体モジュレーターとしてのその活性
ES2727329T3 (es) Compuestos de ácido dimetilbenzoico
US9000043B2 (en) Phenoxyethoxy compounds
MX2014015952A (es) Compuestos de acido dimetil-benzoico.
BR112015026967B1 (pt) Fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
HK1203937B (en) Phenoxyethyl piperidine compounds
AU2014265762B2 (en) Phenoxyethyl dihydro-1H-isoquinoline compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/06/2013, OBSERVADAS AS CONDICOES LEGAIS